Myeloid cells constitute an important part of the immune cell infiltrate in ALL patients (39), suggesting that improved myeloid cell recruitment by CD38 antibodies of the IgA isotype may enhance the efficacy of antibody-based therapeutic approaches in these patients. Here, CD38 is linked to acute lymphoblastic leukemia.